Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,336 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial.
Marchetti M, Barosi G, Balestri F, Viarengo G, Gentili S, Barulli S, Demory JL, Ilariucci F, Volpe A, Bordessoule D, Grossi A, Le Bousse-Kerdiles MC, Caenazzo A, Pecci A, Falcone A, Broccia G, Bendotti C, Bauduer F, Buccisano F, Dupriez B. Marchetti M, et al. Among authors: volpe a. J Clin Oncol. 2004 Feb 1;22(3):424-31. doi: 10.1200/JCO.2004.08.160. J Clin Oncol. 2004. PMID: 14752066 Clinical Trial.
Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence.
Oliva EN, Lauseker M, Aloe Spiriti MA, Poloni A, Cortelezzi A, Palumbo GA, Balleari E, Sanpaolo G, Volpe A, Ricco A, Ronco F, Alati C, D'Errigo MG, Santacaterina I, Kündgen A, Germing U, Latagliata R. Oliva EN, et al. Among authors: volpe a. Cancer Med. 2015 Dec;4(12):1789-97. doi: 10.1002/cam4.523. Epub 2015 Sep 17. Cancer Med. 2015. PMID: 26376955 Free PMC article.
MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidine.
Visani G, Loscocco F, Ruzzo A, Galimberti S, Graziano F, Voso MT, Giacomini E, Finelli C, Ciabatti E, Fabiani E, Barulli S, Volpe A, Magro D, Piccaluga P, Fuligni F, Vignetti M, Fazi P, Piciocchi A, Gabucci E, Rocchi M, Magnani M, Isidori A. Visani G, et al. Among authors: volpe a. Pharmacogenomics J. 2018 May 22;18(3):444-449. doi: 10.1038/tpj.2017.48. Epub 2017 Dec 5. Pharmacogenomics J. 2018. PMID: 29205204
Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy.
Oliva EN, Latagliata R, Laganà C, Breccia M, Galimberti S, Morabito F, Poloni A, Balleari E, Cortelezzi A, Palumbo G, Sanpaolo G, Volpe A, Specchia G, Finelli C, D'Errigo MG, Rodà F, Alati C, Alimena G, Nobile F, Aloe Spiriti MA. Oliva EN, et al. Among authors: volpe a. Leuk Lymphoma. 2013 Nov;54(11):2458-65. doi: 10.3109/10428194.2013.778406. Epub 2013 Mar 27. Leuk Lymphoma. 2013. PMID: 23432724 Clinical Trial.
Health-related quality of life in transfusion-dependent patients with myelodysplastic syndromes: a prospective study to assess the impact of iron chelation therapy.
Efficace F, Santini V, La Nasa G, Cottone F, Finelli C, Borin L, Quaresmini G, Di Tucci AA, Volpe A, Cilloni D, Quarta G, Sanpaolo G, Rivellini F, Salvi F, Molteni A, Voso MT, Alimena G, Fenu S, Mandelli F, Angelucci E. Efficace F, et al. Among authors: volpe a. BMJ Support Palliat Care. 2016 Mar;6(1):80-8. doi: 10.1136/bmjspcare-2014-000726. Epub 2014 Sep 9. BMJ Support Palliat Care. 2016. PMID: 25204541
Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE).
Oliva EN, Candoni A, Salutari P, Palumbo GA, Reda G, Iannì G, Tripepi G, Cuzzola M, Capelli D, Mammì C, Alati C, Cannatà MC, Niscola P, Serio B, Musto P, Vigna E, Volpe A, Melillo LMA, Arcadi MT, Mannina D, Zannier ME, Latagliata R. Oliva EN, et al. Among authors: volpe a. Cancers (Basel). 2023 Apr 24;15(9):2441. doi: 10.3390/cancers15092441. Cancers (Basel). 2023. PMID: 37173908 Free PMC article.
Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Caocci G, Molteni A, Vallisa D, Voso MT, Fenu S, Borin L, Latte G, Alimena G, Storti S, Piciocchi A, Fazi P, Vignetti M, Tura S. Angelucci E, et al. Among authors: volpe a. Eur J Haematol. 2014 Jun;92(6):527-36. doi: 10.1111/ejh.12300. Epub 2014 Apr 10. Eur J Haematol. 2014. PMID: 24580147 Clinical Trial.
Autologous cell therapy for ischemic diabetic foot: a meta-analysis of randomized controlled trials for the development of the Italian guidelines for the treatment of diabetic foot syndrome.
Scatena A, Apicella M, Mantuano M, Ragghianti B, Silverii A, Miranda C, Monge L, Uccioli L, Scevola G, Stabile E, Gargiulo M, Vermigli C; Panel of the Italian Guidelines for the Treatment of Diabetic Foot Syndrome and on behalf of SID and AMD. Scatena A, et al. Acta Diabetol. 2024 Nov 15. doi: 10.1007/s00592-024-02393-z. Online ahead of print. Acta Diabetol. 2024. PMID: 39545964
1,336 results